Switch to:
More From Other Websites
Everything you need to know about the $8.4B acquisition of Synageva May 06 2015
Superbugs Turn Big Pharma, Gov't Focus To Antibiotics Apr 09 2015
Mario Gabelli's Top 5 Stock Picks Mar 31 2015
Farallon Capital Starts New Position in Cubist Pharmaceuticals Mar 20 2015
Tetraphase looks to double its cash with stock offering Mar 10 2015
Layoffs at Cubist come amid a steady flow of senior execs out of Merck Mar 06 2015
Elliott Management exits position in Covidien Mar 04 2015
Elliott Management starts new position in Cubist Pharmaceuticals Mar 02 2015
Prem Watsa's Stock Buys and Sells of Q4 Feb 17 2015
Dana Holding Set to Join the S&P MidCap 400 Jan 20 2015
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market Jan 13 2015
Teixobactin And iChip Promise Hope Against Antibiotic Resistance Jan 08 2015
Cramer's Mad Dash: Pharma movers Dec 24 2014
Approval of new antibiotic by Cubist to help in $100 trillion global fight Dec 22 2014
FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
Merck Begins Tender Offer to Acquire Cubist Dec 19 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK